- Multimodality RT Simulation Workspace provides a single space for multimodality image fusion and contouring
- New imaging platforms MR – Ingenia RT XD – and Spectral CT 7500 support precise treatment planning
- Deepened cross-portfolio collaboration with Elekta utilizes complementary capabilities to further enhance patient care
Amsterdam, the Netherlands and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new innovations that will help improve cancer care across the patient journey at the American Society for Radiation Oncology (ASTRO) annual meeting (Chicago, USA, 24-27 October). During the event, Philips will debut its Multimodality RT Simulation Workspace, a new precision medicine application that provides a vendor-agnostic single space for simulation, multimodality image fusion and contouring. New MR and CT imaging systems tailored for the needs of radiation therapy will also be showcased, delivering breakthroughs in imaging and treatment planning. Philips will also highlight its deepened strategic partnership with Elekta to support the ambition of providing clear care pathways and predictable outcomes for every cancer patient.
Today, cancer care is a long, complex journey through various stages, settings, and providers, putting a significant burden on both patients and clinicians. The number of new cancer cases is expected to rise by about 70% over the next two decades [1]. At the same time, oncology care is transforming, driven by an increasingly precise diagnosis of each tumor, and a continuously expanding range of therapy options. To fully capitalize on these challenges and opportunities, healthcare providers require integrated solutions throughout the entire cancer care pathway, from diagnosis to treatment and follow-up.
“Enhanced through strategic partnerships, our end-to-end oncology solutions span the patient pathway and the multidisciplinary specialties, integrating data and enabling collaboration, all with the aim of improving patient and staff satisfaction and outcomes,” said Ardie Ermers, General Manager Oncology Solutions at Philips. “At this year’s ASTRO meeting we’re highlighting how we’re connecting clinical and operational teams with the information they need to optimize and personalize cancer care.”
Bringing clarity in therapy planning closer to the point of care with Multimodality RT Simulation Workspace
With images and data often siloed in different systems, the complexity of image fusion and contouring can lengthen patient time to treatment. Integrating seamlessly into the simulation workflow, Multimodality RT Simulation Workspace, a new precision medicine application, is designed to help physicians define tumor volume and surrounding organs-at-risk through a versatile multimodality image platform which connects to both Philips and non-Philips imaging devices or a Picture Archiving and Communication System (PACS) to access image datasets such as CT, MR, PET, Spectral CT and Cone Beam CT. These capabilities provide better access to a task-centered, vendor neutral solution that efficiently utilizes all available images and data in one central location.
Innovations in MR and CT simulation deliver advances in imaging and treatment planning
With the company’s strong track record of bringing continuous innovations to expand the role of MRI in radiation therapy, the next-generation Philips MR – Ingenia RT XD – MR simulation platform has been designed around the needs of radiation oncology, combining ease-of-use, streamlined integration and versatility. The platform can be easily adapted for different procedures, including external beam radiation therapy (EBRT), proton therapy and brachytherapy planning. The new Couch Top RT XD with Unity indexing further extends the compatibility between the Philips MR – Ingenia RT XD – and Elekta Unity, supporting greater consistency in both image quality and imaging and positioning workflows that enhance reproducibility, help accelerate learning curves and drive continuity across the care path.
The recently-introduced Spectral CT 7500 system delivers high quality spectral images for every patient on every scan 100% of the time to help improve disease characterization, and reduce rescans and follow-ups, all at the same dose levels as conventional scans. Unlocking the clinical value of dual-energy CT for radiation oncology applications, Spectral CT allows for optimization of lesions that may represent cancer. By capturing additional information such as electron density and effective atomic number, Spectral CT enables physicians to quantify physiological processes such as perfusion and ventilation, enhancing treatment planning.
Philips is collaborating with MIM Software to integrate its Contour ProtégéAI next-generation deep learning segmentation on its CT – Big Bore RT – platform, providing automatically segmented ‘Organ at Risk’ segmentation immediately after the simulation exam [2].
Further expansion of precision medicine application portfolio
Also being introduced at ASTRO, Multidisciplinary Team Orchestrator virtually connects and securely integrates multi-disciplinary teams and data across the patient cancer journey. Together with Multimodality RT Simulation Workspace, applications already available from Philips that advance precision oncology through integrated care, pathway orchestration, and clinical decision support, include:
- Lung Cancer Orchestrator, a proactive patient management system for lung cancer screening and incidental findings and the orchestration of lung cancer care
- Oncology Pathways that are created by oncologists for oncologists, covering both medical and the newly-introduced radiation oncology pathways. Customers become collaborators, providing input into the ever-evolving pathways
- Genomics Workspace, bringing genomic data alongside disease histology and patient phenotype for a comprehensive biomarker-informed diagnostic and therapeutic picture
Partnering to benefit patients throughout the care pathway
In June, Philips and Elekta announced that the two healthcare leaders would deepen their strategic partnership in precise and individualized oncology care. The strengthened strategic partnership intends to further deliver an excellent experience in diagnosis and adaptive, personalized treatments for clinicians, shorter treatment times and precise therapy for patients, and lowered costs of care for healthcare providers. As part of the partnership, Philips will develop seamless integration between its precision medicine applications and Elekta’s MOSAIQ Plaza integrated radiotherapy software suite, enhancing end-to-end decision making and treatment implementation.
For more information about Philips’ presence at ASTRO 2021 follow @PhilipsLiveFrom for updates throughout the event.
[1] WHO International Agency for Research on Cancer https://gco.iarc.fr/today/
[2] Big Bore RT with Contour ProtégéAI is only available in the USA
Multimodality RT Simulation Workspace is a new feature of the TumorLoc module, part of Pinnacle RTPS. Both TumorLoc and Pinnacle are FDA cleared
For further information, please contact:
Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978 221 8919
E-mail: kathy.oreilly@philips.com
Mark Groves
Philips Global Press Office
Tel.: +31 631 639 916
Email: mark.groves@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments